This is a First-in-Human, single arm, open-label, multi-national study designed to determine
the safety, tolerability and preliminary efficacy of MCLA 117.
Phase:
Phase 1
Details
Lead Sponsor:
Merus N.V.
Collaborators:
CROS NT CSM Europe sa Kinesis Pharma B.V. LGC Limited Pharmaceutical Research Associates QPS Netherlands B.V. VU University Medical Center